Skip to main content

About Michigan's Cancer Genomics Program

The Cancer Genomics Program works to reduce the impact of hereditary cancer on the people of Michigan and their families.

Our ultimate goal is to lower the incidence and mortality of hereditary cancers, especially breast cancer at a young age, ovarian cancer, endometrial cancer, and colorectal cancer, through the promotion of cancer genomics best practices in the state. These practices include the use of evidence-based guidelines for the screening and management of hereditary cancer syndromes.

The program and its partners monitor cancer genomics practices in the state, increase awareness of hereditary cancers, promote national and state genomic policies, and provide training and education about cancer genomics to Michigan residents, health care professionals and policymakers. Our program has been awarded cooperative agreements with the Centers for Disease Control and Prevention (CDC) since 2003.

General Information about Hereditary Cancers

Hereditary Breast and Ovarian Cancer (HBOC)

Lynch Syndrome (LS)

Resources for Patients and Families

Resources for Providers

Cancer Genomics Policy in Michigan

State Resources

 

National Resources

 

Contact Us

If you have questions, call the MDHHS Genetic Information Line at 1-866-852-1247 or email genetics@michigan.gov. For cancer genetic counseling and testing services in your area, visit the Directory of Clinical Cancer Genetic Services in Michigan.

Public Health Genomics Section 
Lifecourse Epidemiology and Genomics Division  
P.O. Box 30195
333 S. Grand Avenue
Lansing, Michigan 48909-30195

 

Funding for this program was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed in written materials, publications, or webpages do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Last updated: 6/23/2022